KALV - KalVista Pharmaceuticals, Inc.
NEXT EARNINGS:
May 5, 2026
EPS Est: $-0.40
|
Rev Est: $39.7M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$32.33
DETAILS
HIGH:
$37.00
LOW:
$28.00
MEDIAN:
$32.00
CONSENSUS:
$32.33
UPSIDE:
67.25%
Market Cap:
990.13M
Volume:
2,031,910
Avg Volume:
982,154
52 Week Range:
9.235-19.95
Sector:
Healthcare
Industry:
Biotechnology
Beta:
-0.29
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
150
IPO Date:
2015-04-09
EPS (TTM):
-3.20
P/E Ratio:
-3.73
Revenue (TTM):
75.04M
Total Assets:
335.38M
Total Debt:
269.02M
Cash & Equiv:
N/A
Rev Growth (5Y):
-100.0%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-84.8%
Debt/Equity:
0.07
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-03-24 | $-0.11 | $-0.54 | +79.6% | $59.9M | $40.4M | +48.5% |
| 2025-11-10 | $-0.92 | $-0.96 | +4.2% | $13.7M | $32.3M | -57.6% |
| 2025-09-11 | $-1.12 | $-0.91 | -23.1% | $1.4M | $12.6M | -88.7% |
| 2025-07-10 | $-0.99 | $-0.77 | -28.6% | — | $4.2M | — |
| 2025-03-12 | $-0.92 | $-0.89 | -3.4% | — | — | — |
| 2024-12-05 | $-0.91 | $-0.91 | 0.0% | — | — | — |
| 2024-09-05 | $-0.87 | $-0.91 | +4.4% | — | — | — |
| 2024-07-11 | $-1.02 | $-0.73 | -39.7% | — | — | — |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 12.69M | 16.13M | 8.39M | 1.50M | 2.13M | 1.80M | 415,000 |
| Net Income | (183.44M) | (126.64M) | (92.91M) | (82.34M) | (46.24M) | (29.12M) | (20.82M) | (15.80M) | (18.60M) | (11.44M) | (7.23M) | (5.68M) |
| EPS | -3.69 | -3.44 | -3.33 | -3.36 | -2.33 | -1.64 | -1.38 | -1.53 | -1.92 | -2.40 | -6.17 | -7.83 |
| Total Assets | 250.77M | 235.40M | 183.20M | 203.88M | 272.01M | 92.53M | 118.13M | 61.39M | 34.34M | 24.75M | 6.64M | 10.11M |
| Total Debt | 6.31M | 7.32M | 8.23M | 8.19M | 5.91M | 1.65M | 54,000 | 279,000 | 0 | 4.61M | 6.57M | 3.06M |
| Cash & Equivalents | 98.64M | 31.79M | 56.24M | 30.73M | 50.59M | 15.79M | 32.01M | 51.05M | 30.95M | 21.76M | 3.90M | 9.78M |
| Operating Cash Flow | (152.91M) | (89.23M) | (75.26M) | (78.13M) | (30.17M) | (44.82M) | (36.37M) | 10.56M | (23.72M) | (13.16M) | (6.37M) | (4.86M) |
| Free Cash Flow | (153.34M) | (89.67M) | (76.46M) | (79.06M) | (30.25M) | (45.04M) | (37.45M) | 9.13M | (23.80M) | (13.17M) | (6.49M) | (4.88M) |
| FCF per Share | -3.09 | -2.44 | -2.74 | -3.23 | -1.58 | -2.54 | -2.48 | 0.88 | -2.45 | -2.76 | -5.55 | -6.73 |
| Book Value | 95.39M | 206.58M | 161.03M | 185.09M | 257.19M | 83.75M | 96.74M | 27.25M | 31.33M | 21.50M | (44.18M) | (33.71M) |
| Cash & ST Investments | 187.65M | 210.40M | 149.38M | 166.20M | 248.93M | 67.71M | 100.81M | 51.05M | 30.95M | 21.76M | 3.90M | 9.78M |
| ROC Equity | -1.92 | -0.61 | -0.58 | -0.44 | -0.18 | -0.35 | -0.22 | -0.58 | -0.59 | -0.53 | N/A | N/A |